KCNA5 and cardiovascular disorder: In our previous studies, the inhibitory activity on the shaker-related subfamily of voltage-gated channels (Kv1.1–Kv1.5) was investigated, and potential drug targets for the treatment of diverse disease processes, ranging from cancer to autoimmune diseases to metabolic, neurological and cardiovascular disorders [19], of ATXs were tested, and it turned out several ATXs had selective and strong blocking inhibitory effects on the Kv1.5 K+ channel [10,11,12,20,21,22].